GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹6,376 Cr | ₹5,967 Cr | ₹5,819 Cr | ₹4,546 Cr | ₹4,689 Cr |
What is the latest Total Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹6,376 Cr |
| Mar2025 | ₹5,967 Cr |
| Mar2024 | ₹5,819 Cr |
| Mar2023 | ₹4,546 Cr |
| Mar2022 | ₹4,689 Cr |
How is Total Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹6,376 Cr | 6.86 | |
| Mar2025 | ₹5,967 Cr | 2.55 | |
| Mar2024 | ₹5,819 Cr | 27.99 | |
| Mar2023 | ₹4,546 Cr | -3.05 | |
| Mar2022 | ₹4,689 Cr | - | |
Compare Total Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹71,041.0 Cr | 5.5% | 14.9% | 26.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹460,696.0 Cr | 0.5% | -4% | 15.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,063.0 Cr | 9.1% | 18.2% | 47.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,515.0 Cr | 3.6% | 3.4% | 36.4% | Stock Analytics | |
| CIPLA | ₹114,554.0 Cr | -1.2% | -3.3% | -10.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,308.6 Cr | -1.4% | 2.9% | -8% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 5.5% |
14.9% |
26.8% |
| SENSEX | -0.4% |
-0.5% |
-5.8% |
You may also like the below Video Courses